[go: up one dir, main page]

AR072815A1 - COMPOSITIONS AND USES OF ACTIVE ANTIVIRAL PHARMACEUTICAL AGENTS - Google Patents

COMPOSITIONS AND USES OF ACTIVE ANTIVIRAL PHARMACEUTICAL AGENTS

Info

Publication number
AR072815A1
AR072815A1 ARP090102719A ARP090102719A AR072815A1 AR 072815 A1 AR072815 A1 AR 072815A1 AR P090102719 A ARP090102719 A AR P090102719A AR P090102719 A ARP090102719 A AR P090102719A AR 072815 A1 AR072815 A1 AR 072815A1
Authority
AR
Argentina
Prior art keywords
compositions
pharmaceutical agents
pleconaril
antiviral pharmaceutical
active antiviral
Prior art date
Application number
ARP090102719A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR072815A1 publication Critical patent/AR072815A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Varias realizaciones del presente proporcionan un método para tratar, reducir o minimizar las exacerbaciones del asma en seres humanos que son PCR+ para un rinovirus, que incluye administrar por inhalacion oral o intranasal una cantidad terapéuticamente efectiva de pleconaril. Reivindicacion 2: El método de la reivindicacion 1, en el que se administra pleconaril mediante un pulverizador nasal. Reivindicacion 16: El método de la reivindicacion 15, en el que se administra pleconaril mediante un inhalador de polvo seco.Several embodiments of the present provide a method for treating, reducing or minimizing asthma exacerbations in humans that are PCR + for a rhinovirus, which includes administering a therapeutically effective amount of pleconaril by oral or intranasal inhalation. Claim 2: The method of claim 1, wherein pleconaril is administered by a nasal spray. Claim 16: The method of claim 15, wherein pleconaril is administered by a dry powder inhaler.

ARP090102719A 2008-07-17 2009-07-16 COMPOSITIONS AND USES OF ACTIVE ANTIVIRAL PHARMACEUTICAL AGENTS AR072815A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8158308P 2008-07-17 2008-07-17

Publications (1)

Publication Number Publication Date
AR072815A1 true AR072815A1 (en) 2010-09-22

Family

ID=41119278

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102719A AR072815A1 (en) 2008-07-17 2009-07-16 COMPOSITIONS AND USES OF ACTIVE ANTIVIRAL PHARMACEUTICAL AGENTS

Country Status (3)

Country Link
AR (1) AR072815A1 (en)
TW (1) TW201016215A (en)
WO (1) WO2010009288A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG184430A1 (en) 2010-04-15 2012-11-29 Biota Scient Management Compound for treatment of respiratory condition or disease
WO2015023524A1 (en) * 2013-08-15 2015-02-19 Antivirus Therapeutics Methods and compositions for increasing the effectiveness of antiviral agents
EP4241771A3 (en) 2013-11-08 2023-11-22 Antivirus Therapeutics Methods and compositions for treating sepsis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017505A2 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
JP2009526064A (en) * 2006-02-09 2009-07-16 シェーリング コーポレイション Pharmaceutical formulation
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations

Also Published As

Publication number Publication date
WO2010009288A1 (en) 2010-01-21
TW201016215A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
CL2007002121A1 (en) COMPOUNDS DERIVED FROM PIRAZOLES, GLUCOQUINASA ACTIVATORS; PREPARATION PROCESS OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND USE FOR THE TREATMENT OF DISEASES AND / OR METABOLIC DISORDERS, AS DIAB
BR112015010663A2 (en) sustained release ruxolitinib dosage forms
UY35391A (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANO-3-CARBOXILICO (BENCIL-CYANOMETIL) -CATPSIN C INHIBITING REPLACED MEASURES
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
BR112015005227A2 (en) glycosylceramide synthase inhibitors
MX2011009847A (en) Anthelmintic agents and their use.
BR112013028572B8 (en) NOZZLES FOR NASAL DRUG DELIVERY
CL2007002099A1 (en) COMPOUNDS DERIVED FROM 3H-ESPIRO (1-BENZOFURAN-2,4'-PIPERIDINA); PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF RESPIRATORY DISEASES, SUCH AS COPD AND ASTHMA.
BR112013027119A2 (en) new ligand-drug conjugates (adcs) and their use
CR20140108A (en) CYCLOPROPANOAMINE COMPOUND
BR112012009376B8 (en) solid pharmaceutical composition comprising a sglt-2 inhibitor and its pharmaceutical dosage form
CO6470810A2 (en) A NEW FORMULATION OF DICLOFENACO
BR112012000204A8 (en) PHARMACEUTICAL COMPOSITION IN UNIT DOSAGE FORM INCLUDING APOMORPHINE AND ITS USE
PH12014500551A1 (en) Pharmaceutical composition for inhalation
MX344222B (en) A NEW FORMULATION OF NAPROXENE.
UY31687A1 (en) NEW DOSAGE AND FORMULATION
EA201171283A1 (en) NEW TECHNOLOGY OF MELOXICAM MANUFACTURE
CL2011002100A1 (en) Pharmaceutical composition comprising (4ar, 10ar) -1-n-propyl-1,2,3,4,4a, 5,10,10a-octahydro-benzo [g] quinolin-6,7-diol and its derivatives, to administration by oral mucosa, nasal or through the skin; and its use for the treatment of Parkinson's disease.
BR112012027080A2 (en) organic compositions for treating beta - ene related diseases
MX2013008175A (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof.
AR085056A1 (en) DIMALEATE OF 9- [4- (3-CHLORINE-2-FLUORO-PHENYLAMINE) -7-METOXI-QUINAZOLIN-6-ILOXI] -1,4-DIAZA-ESPIRO [5.5] UNDECAN-5-ONA, ITS USE AS A MEDICINAL PRODUCT AND HIS PREPARATION
MX2020003436A (en) Dry powder inhaler and methods of use.
ECSP11011101A (en) CYCLOUNDECADEPSIPEPTIDE COMPOUNDS AND THE USE OF SUCH COMPOUNDS AS A MEDICINAL PRODUCT
UY31133A1 (en) "SUBSTITUTED OXAZOLIDINONES AND ITS USE"
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal